Pound sells off on Brexit woesThe pound is down 2% against the U.S dollar in the past couple of days, on growing prospects that the United Kingdom will leave the European Union without a trade agreement.
Brexit talks are set to continue this week, with UK’s Prime Minister Boris Johnson playing hardball with European Officials. He has imposed a October 15 deadline, to which he plans to quit Brexit talks if no deal is reached.
The pounds have mostly forgotten Brexit, with the Coronavirus pandemic guiding everyone’s attention away from the non-completion of Brexit.
Seema Shah, Portfolio manager at Principal Global Investors, stated that headlines over the weekend were a “timely reminder that, while the markets have been distracted by the UK’s struggle to rejuvenate the economy, Brexit negotiations have quietly been going nowhere.”
The main issues include competition, fisheries, and solving disputes.
UK government undermining Brexit, pushing pound lower
Further downwards pressure came from the revelation of the UK government is planning to release legislation that would override critical parts of the withdrawal agreement – notably the deal that would undermine the agreement that Boris Johnson signed last year to avoid a return to a hard border.
The pound has been rallying since its March lows, up 14.13%. However, it has underperformed compared to its peers. For example, the Australian dollar has rallied 31% since its March lows.
The main issue for the pound comes from its appreciation, not discounting Brexit talks. As headlines start to creep up about Brexit near Boris’ October 15 date, the pound’s volatility will increase. Petr Krapta, a currency strategist at ING bank, stated that “the Brexit head is back on and sterling is, in our view, unprepared.” This comes at a time when the UK’s grip on the Coronavirus continues to slip, with daily cases spiking, recording the highest number of daily Coronavirus cases since May.
Unitedkingdom
$ADAP can rise in the next daysContextual immersion trading strategy idea.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States.
Friday morning the company presented positive data on its experimental cell therapy, which is designed to treat a range of cancers. It causes a rise in the share price. I see some preconditions the share price will continue growing.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $11,85;
stop-loss — $11,18.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
#GBPCHF [MAJOR SHORT] ABC Correction or The Start Of Wave 3!Weekly analyis of GBPCHF! Either way it is a short because, if it is wave B we can still catch the move down to complete C.
If it is the start of Wave 3, then we are catching the strongest move in the 5 wave sequence.
Please follow one of these to support the freebies!
www.PipsUniversity.com
www.Twitter.com
www.Instagram.com